Methods of treating cancer and enhancing immune responses...

Details Methods of treating cancer and enhancing immune responses... Methods of treating cancer and enhancing immune responses...

2005-08-25

2008-03-04

Gambel, Phillip (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Monoclonal antibody or fragment thereof

C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S173100, C530S387100, C530S387300, C530S388200, C530S388220, C530S388700, C530S388730

Reexamination Certificate

active

07338660

ABSTRACT:
The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.

REFERENCES:
patent: 4399216 (1983-08-01), Axel et al.
patent: 4510245 (1985-04-01), Cousens et al.
patent: 4634665 (1987-01-01), Axel et al.
patent: 4740461 (1988-04-01), Kaufman
patent: 4912040 (1990-03-01), Kaufman et al.
patent: 4959455 (1990-09-01), Clark et al.
patent: 4968615 (1990-11-01), Koszinowski et al.
patent: 5151510 (1992-09-01), Stec et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5179017 (1993-01-01), Axel et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5545806 (1996-08-01), Lonberg et al.
patent: 5545807 (1996-08-01), Surani et al.
patent: 5569825 (1996-10-01), Lonberg
patent: 5587458 (1996-12-01), King et al.
patent: 5591669 (1997-01-01), Krimpenfort et al.
patent: 5612205 (1997-03-01), Kay et al.
patent: 5625126 (1997-04-01), Lonberg et al.
patent: 5633425 (1997-05-01), Lonberg et al.
patent: 5643763 (1997-07-01), Dunn et al.
patent: 5661016 (1997-08-01), Lonberg et al.
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5721367 (1998-02-01), Kay et al.
patent: 5741957 (1998-04-01), Deboer et al.
patent: 5747498 (1998-05-01), Schnur et al.
patent: 5750172 (1998-05-01), Meade et al.
patent: 5756687 (1998-05-01), Denman et al.
patent: 5770429 (1998-06-01), Lonberg et al.
patent: 5789215 (1998-08-01), Berns et al.
patent: 5789650 (1998-08-01), Lonberg et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5814318 (1998-09-01), Lonberg et al.
patent: 5827690 (1998-10-01), Meade et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5861510 (1999-01-01), Piscopio et al.
patent: 5863949 (1999-01-01), Robinson et al.
patent: 5874082 (1999-02-01), de Boer
patent: 5877305 (1999-03-01), Huston et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 5916771 (1999-06-01), Hori et al.
patent: 5939598 (1999-08-01), Kucherlapati et al.
patent: 5959177 (1999-09-01), Hein et al.
patent: 5985615 (1999-11-01), Jakobovits et al.
patent: 5994619 (1999-11-01), Stice et al.
patent: 5998209 (1999-12-01), Jokobovits et al.
patent: 6046037 (2000-04-01), Hiatt et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6075181 (2000-06-01), Kucherlapati et al.
patent: 6091001 (2000-07-01), Jakobovits et al.
patent: 6114598 (2000-09-01), Kucherlapati et al.
patent: 6130364 (2000-10-01), Jakobovits et al.
patent: 6150584 (2000-11-01), Kucherlapati et al.
patent: 6162963 (2000-12-01), Kucherlapati et al.
patent: 6312693 (2001-11-01), Aruffo et al.
patent: 6417429 (2002-07-01), Hein et al.
patent: 6440418 (2002-08-01), Black et al.
patent: 6482411 (2002-11-01), Ahuja et al.
patent: 6517529 (2003-02-01), Quinn et al.
patent: 6713610 (2004-03-01), Kucherlapati et al.
patent: 6843989 (2005-01-01), Siegall et al.
patent: 2001/0026932 (2001-10-01), Thomas et al.
patent: 2002/0142358 (2002-10-01), Mikayama et al.
patent: 2003/0059427 (2003-03-01), Force et al.
patent: 2003/0118588 (2003-06-01), Diehl et al.
patent: 0 216 846 (1987-04-01), None
patent: 0 256 055 (1988-02-01), None
patent: 0 323 997 (1989-07-01), None
patent: 0 338 841 (1989-10-01), None
patent: 0 606 046 (1994-07-01), None
patent: 0 780 386 (1997-06-01), None
patent: 0 818 442 (1998-01-01), None
patent: 0 931 788 (1999-07-01), None
patent: 0 945 864 (1999-09-01), None
patent: 1 004 578 (2000-05-01), None
patent: 8012700 (1996-01-01), None
patent: 2000 124084 (2000-09-01), None
patent: 2000 109255 (2002-01-01), None
patent: WO 90/05719 (1990-05-01), None
patent: WO 91/10741 (1991-07-01), None
patent: WO 91/17271 (1991-11-01), None
patent: WO 92/01047 (1992-01-01), None
patent: WO 92/09690 (1992-06-01), None
patent: WO 92/15679 (1992-09-01), None
patent: WO 92/18619 (1992-10-01), None
patent: WO 92/20791 (1992-11-01), None
patent: WO 93/01288 (1993-01-01), None
patent: WO 93/06213 (1993-04-01), None
patent: WO 94/02602 (1994-02-01), None
patent: WO 95/09653 (1995-04-01), None
patent: WO 95/19970 (1995-07-01), None
patent: WO 95/21613 (1995-08-01), None
patent: WO 96/27583 (1996-09-01), None
patent: WO 96/33172 (1996-10-01), None
patent: WO 96/33735 (1996-10-01), None
patent: WO 96/34096 (1996-10-01), None
patent: WO 97/13760 (1997-04-01), None
patent: WO 97/22596 (1997-06-01), None
patent: WO 97/32856 (1997-09-01), None
patent: WO 98/02434 (1998-01-01), None
patent: WO 98/02437 (1998-01-01), None
patent: WO 98/02438 (1998-01-01), None
patent: WO 98/03516 (1998-01-01), None
patent: WO 98/07697 (1998-02-01), None
patent: WO 98/14451 (1998-04-01), None
patent: WO 98/16654 (1998-04-01), None
patent: WO 98/24893 (1998-06-01), None
patent: WO 98/30566 (1998-07-01), None
patent: WO 98/33768 (1998-08-01), None
patent: WO 98/34915 (1998-08-01), None
patent: WO 98/34918 (1998-08-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 98/50433 (1998-11-01), None
patent: WO 98/52976 (1998-11-01), None
patent: WO 98/54093 (1998-12-01), None
patent: WO 99/07675 (1999-02-01), None
patent: WO 99/10349 (1999-03-01), None
patent: WO 99/16755 (1999-04-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 99/29667 (1999-06-01), None
patent: WO 99/35132 (1999-07-01), None
patent: WO 99/35146 (1999-07-01), None
patent: WO 99/45031 (1999-09-01), None
patent: WO 99/52889 (1999-10-01), None
patent: WO 99/52910 (1999-10-01), None
patent: WO 99/53049 (1999-10-01), None
patent: WO 99/61057 (1999-12-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 99/62890 (1999-12-01), None
patent: WO 00/09560 (2000-02-01), None
patent: WO 00/34317 (2000-05-01), None
patent: WO 00/37504 (2000-06-01), None
patent: WO 01/56603 (2001-08-01), None
patent: WO 01/83755 (2001-11-01), None
Alexandroff et al., “Role for CD40-CD40 ligand interactions in the immune response to solid tumours.”Molecular Immunology37(9):515-526 (2000).
Bendig, “Humanization of Rodent Monoclonal Antibodies by CDR Grafting,”Methods: A Companion to Methods in Enzymology8:83-93 (1995).
Francisco J.A. et al., “Agonistic properties and in vivo antitumor activity of the Anti-cd40 antibody SGN-14,”Cancer research60:3255-3231 (2000).
Grohmann et al., “CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells.”Journal of Immunology166(1):277-283 (2001).
Mierlo et al., “CD40 stimulation leads to effective therapy of CD40-tumors through induction of strong systemic cytotoxic T lymphocyte immunity.”Proceedings of the National Academy of SciencesUSA 99(8):5561-5566 (2002).
Szocinski et al., “Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: Induction of bax.”Blood100(1):217-223 (2002).
Todryk et al., “CD40 ligation for immunotherapy of solid tumors.”Journal of Immunological Methods248(1/2):139-147 (2001).
Turner et al., “Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.”Journal of Immunology166(1):89-94 (2001).
United States Patent and Trademark Office, “Notice of Allowance and Fee(s) Due,” U.S. Appl. No. 10/292,088, filed Jun. 26, 2007.
United States Patent and Tr

Affiliated with

Also associated with

Rating

Methods of treating cancer and enhancing immune responses... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating cancer and enhancing immune responses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating cancer and enhancing immune responses... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3964116